BBIO Director Sells $3.9M in Stock Following Option Exercise
BridgeBio Pharma, Inc.
Subscribe to track BBIO
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BBIO Director Sells $3.9M in Stock Following Option Exercise
Company: BridgeBio Pharma, Inc. (BBIO) Form: 4 | Filed: 2025-11-07 Significance: Low
Insider: DANIELS RONALD J Title: null | Relationship: Director
Transaction: • Type: Sell (following option exercise) • Shares: 61,031 • Price: $63.72 • Value: $3,889,200 • Owned After: 16,991
Key Insight: This is a common 'exercise-and-sell' transaction where the insider exercised options and immediately sold the shares, likely to cover costs and realize gains. The transaction value is minor relative to the company's $11.9B market cap.
Market Context: The sale represents a small fraction (0.032%) of the company's total shares outstanding.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: BridgeBio Pharma, Inc. (BBIO)
Executive Summary
- Trading Significance: Low
- Key Takeaway: A director conducted a routine "exercise-and-sell" transaction, realizing gains on vested stock options with a total sale value of approximately $3.9 million.
- Market Impact: The transaction is not material, representing a negligible percentage of the company's market capitalization and shares outstanding.
Company Information
| Field | Value |
|---|---|
| Company | BridgeBio Pharma, Inc. |
| Ticker Symbol | BBIO |
| CIK | 0001743881 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | DANIELS RONALD J |
| CIK | 0001164475 |
| Title/Position | null |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-11-06 |
| Transaction Code | S (Sale) |
| Security Type | Common Stock |
| Shares Involved | 61,031 |
| Price Per Share | $63.7217 (Weighted Avg) |
| Total Value | $3,889,199.95 |
| Shares Owned After | 16,991 |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $3,889,200 |
| % of Market Cap | 0.033% |
| Shares Transacted | 61,031 |
| % of Shares Outstanding | 0.032% |
| Post-Transaction Ownership | 16,991 shares (0.009% of outstanding) |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The $3.9M sale is insignificant against BridgeBio's $11.94 billion market capitalization.
- Transaction Significance: The sale was part of an option exercise (Code 'M'), a common way for executives to liquidate vested compensation. Such transactions are typically not seen as strong indicators of an insider's forward-looking sentiment.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is a routine exercise-and-sell, which is common for compensation purposes. The size of the sale is immaterial relative to the company's market cap and daily trading volume.
Volume & Sentiment
- Expected Volume Impact: Minimal. The transaction size is unlikely to have a noticeable impact on trading volume.
- Sentiment Indicator: Neutral. This type of transaction is generally not interpreted as a bullish or bearish signal.
Additional Context
Transaction Notes
- Special Circumstances: The filing shows a 'M' transaction (exercise of 61,031 options at $34.65) followed by an 'S' transaction (sale of 61,031 shares at ~$63.72). This confirms it as an exercise-and-sell to realize gains.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.